fda glp-1 warning october 2025 letters target marketers of unapproved weight loss drugs FDA Issues Warning Letters to

Efficacy and safety of lixisenatide once-daily versus exenatide twice-daily in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-X) [abstract 786]

Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery SystemsA Literature Review

The medication in a troche is absorbed directly into the bloodstream through the rich network of blood vessels in the oral mucosa

Stopping GLP-1 drugs can quickly erase cardiovascular benefits Even brief interruption tied to change in risk of heart attack, stroke and death Sara Moser and Alaska Adams / WashU Medicine Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S

Your body is eating less, losing fat, and recalibrating how it perceives temperature